LINC01133: a molecule that helps triple-negative breast cancer hide from the immune system
The long non-coding RNA LINC01133 as a novel determinant of immune evasion in triple-negative breast cancer
This project explores whether blocking a molecule called LINC01133 can reduce growth and immune hiding in triple-negative breast cancer, a form that often affects younger African and Latino women.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | VA Boston Health Care System NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11264831 on NIH RePORTER |
What this research studies
Researchers found that a long RNA called LINC01133 is linked to aggressive triple-negative breast cancer and may help tumors start, spread, and avoid the immune system. In the lab they examine tumor cells' RNA patterns, test how LINC01133 changes cancer cell and immune cell behavior, and use mouse models to watch tumor growth and immune interactions. They also use antisense oligonucleotides (short RNA-blocking molecules) to turn off LINC01133 and see whether tumors slow down. The work connects lab findings to clinical tumor data to guide whether LINC01133 could become a treatment target for people with TNBC.
Who could benefit from this research
Good fit: Patients with triple-negative breast cancer—especially those with metastatic or treatment-refractory disease or tumors that show high LINC01133 levels—would be the most likely candidates for future trials based on this work.
Not a fit: People with hormone receptor–positive or HER2-positive breast cancers, or TNBC patients whose tumors lack high LINC01133 expression, may not benefit from LINC01133-targeted approaches.
Why it matters
Potential benefit: If successful, this work could lead to new therapies that make triple-negative breast cancers less aggressive and more responsive to the immune system and existing treatments.
How similar studies have performed: Antisense oligonucleotides have worked in other diseases and some preclinical cancer models, but targeting LINC01133 in TNBC is a novel approach that has not yet been tested in people.
Where this research is happening
Boston, United States
- VA Boston Health Care System — Boston, United States (Active)
Researchers
- Principal investigator: Karnoub, Antoine Elias — VA Boston Health Care System
- Study coordinator: Karnoub, Antoine Elias
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.